论文部分内容阅读
目的探讨奈达铂联合吉西他滨治疗非小细胞肺癌的临床疗效和安全性。方法选取2011年8月至2013年8月间我院收治的非小细胞肺癌患者120例,按照就诊顺序将其随机分为观察组和对照组,每组各60例。对照组患者采用顺铂联合长春瑞滨化疗方案,观察组患者采用奈达铂联合吉西他滨化疗方案。21d为1个疗程,2个疗程后评价近期疗效和不良反应发生情况。结果观察组患者有效率(OR)为53.3%,疾病控制率(DCR)为88.3%,显著高于对照组患者的38.3%和68.3%(2=7.58,8.01;P<0.05);两组患者主要不良反应为骨髓抑制及胃肠道反应,观察组患者恶心呕吐、腹泻、血小板减少及白细胞减少发生率分别为38.3%、21.7%、40.0%和33.3%,均明显低于对照组(2=9.47,8.82,6.75,7.16;P<0.05)。结论奈达铂联合吉西他滨治疗非小细胞肺癌疗效显著,不良反应小且患者耐受性好,值得推广。
Objective To investigate the clinical efficacy and safety of nedaplatin plus gemcitabine in the treatment of non-small cell lung cancer. Methods A total of 120 patients with non-small cell lung cancer who were admitted to our hospital from August 2011 to August 2013 were randomly divided into observation group and control group according to the order of treatment, 60 cases in each group. Patients in the control group were treated with cisplatin plus vinorelbine, and those in the observation group were treated with nedaplatin plus gemcitabine. 21d for a course of treatment, evaluation of 2 courses of treatment and adverse reactions in the near future. Results The effective rate (OR) of the observation group was 53.3%, the disease control rate (DCR) was 88.3%, significantly higher than that of the control group (38.3% vs 68.3%, 2 = 7.58 and 8.01, P <0.05) The main adverse reactions in patients were myelosuppression and gastrointestinal reactions. The incidence of nausea, vomiting, diarrhea, thrombocytopenia and leukopenia in the observation group were 38.3%, 21.7%, 40.0% and 33.3%, respectively, which were significantly lower than those in the control group 2 = 9.47,8.82,6.75,7.16; P <0.05). Conclusion Nedaplatin combined with gemcitabine is effective in treating non-small cell lung cancer with small adverse reactions and good tolerability. It is worthy of promotion.